earticle

영어

Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has spread rapidly, infecting millions of people worldwide. On March 11, 2020, the World Health Organization declared coronavirus disease (COVID-19) a pandemic owing to the worldwide spread of SARS-CoV-2, which created an unprecedented burden on the global healthcare system. In this context, there are increasing concerns regarding co-infections with other respiratory viruses, such as the influenza virus. In this study, clinical data of patients infected with SARS‑CoV‑2 and other respiratory viruses were compared with patients infected with SARS‑CoV‑2 alone. The hematology and blood biochemistry results of 178 patients infected with SARS‑CoV‑2 , who were tested on admission, were retrospectively reviewed. In patients with SARS‑CoV‑2 and adenovirus co-infection, C-reactive protein levels were elevated on admission, whereas lactate dehydrogenase (LDH), prothrombin time, international normalized ratio, activated partial thromboplastin clotting time, and bilirubin values were all within the normal range. Moreover, patients with SARS‑CoV‑2 and human bocavirus co-infection had low LDH and high bilirubin levels on admission. These findings reveal the clinical features of respiratory virus and SARS‑CoV‑2 co-infections and support the development of appropriate approaches for treating patients with SARS-CoV-2 and other respiratory virus co-infections.